Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing’s sarcoma cells

PURPOSE: Polo-like kinase 4 (PLK4) inhibitors, such as CFI-400945 and centrinone, are emerging as promising antineoplastic agents. However, their effectiveness against Ewing’s sarcoma, a highly aggressive childhood cancer, remains to be established. METHODS: CFI-400945 and centrinone were tested in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerschner-Morales, Sophie L., Kühne, Marie, Becker, Sabine, Beck, James F., Sonnemann, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519924/
https://www.ncbi.nlm.nih.gov/pubmed/32770382
http://dx.doi.org/10.1007/s00432-020-03346-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519924/
https://www.ncbi.nlm.nih.gov/pubmed/32770382
http://dx.doi.org/10.1007/s00432-020-03346-z

Ejemplares similares